about
Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaborationHighlights from the 2016 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): 25-27 May, Marseille, FranceEffect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical studyWhy are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?Plasma Ribavirin Trough Concentrations at Week 4 Predict Hepatitis C Virus (HCV) Relapse in HIV-HCV-Coinfected Patients Treated for Chronic Hepatitis CPredictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic studyPlasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progressionHIV entry inhibitors: mechanisms of action and resistance pathwaysGeographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysisCorrection: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-AnalysisDifferences in the length of gag proteins among different HIV type 1 subtypes.Elite HIV controllers: myth or reality?The global spread of HIV-1 subtype B epidemic.HIV type 2 epidemic in Spain: challenges and missing opportunities.Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma.Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children.Indinavir-induced thrombocytopenia.Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis.Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA.Reliability of a new recombinant immunoblot assay (RIBA HIV-1/HIV-2 SIA) as a supplemental (confirmatory) test for HIV-1 and HIV-2 infections.Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapyPrevalence of human immunodeficiency virus type 1 (HIV-1) non-B subtypes in foreigners living in Madrid, Spain, and comparison of the performances of the AMPLICOR HIV-1 MONITOR version 1.0 and the new automated version 1.5.Molecular epidemiology and clinical features of human T cell lymphotropic virus type 1 infection in SpainPopulation pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent.Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O.Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort.Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library.Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART.[Pharmacokinetics, interactions and mechanism of action of maraviroc].Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. October 2000.Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor.Genetic mechanisms of resistance to NRTI and NNRTI.Genetic mechanisms of resistance to protease inhibitors and entry inhibitors.Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients.Mechanisms of resistance to antiretroviral drugs--clinical implications.
P50
Q24792432-DA6CE89E-4846-4877-A57B-87D6179D7D4EQ26700018-53BA8EF1-97F0-46A5-931A-C9A6C6D68EEBQ27472607-509DE5D7-CA11-40F6-B331-1E8F80CAAA42Q27487167-5BC2972E-6B17-4A9B-BF34-C60C280509E9Q27491326-0189221D-1887-47B0-B346-2A34B66BD9EAQ28243084-D5A74526-AADB-4B75-A136-2A1D7DB9D8F7Q28286926-9F3142DF-B426-4ED6-B6E1-320E680A1196Q28290133-1B3B82AB-C656-49C7-997F-511B8F370AAEQ28296162-5EA68D1B-BF73-41AD-B124-6735F5A71C93Q28545866-9672FA64-389D-40AD-AB16-212AC5EA98B8Q28547717-9CBFC301-A517-415B-A6EB-C060706566D0Q30351626-85C4EFDF-7923-4AE5-9D82-DC348058FB6FQ30367358-AFEEA602-C327-4637-BCDD-38ED96DC8311Q30388926-4D5C6A26-E20F-4852-95C6-241D222257D7Q30400500-34CBEC47-3C1A-435D-B56F-1B3822638C0BQ30620900-5FBDACBF-5FB0-491C-8EE4-3A5FEFE8C59BQ33269695-B5CB0DB0-BC34-4F42-9978-8EED7A01D010Q33287247-267B873B-75EA-4616-B15C-7F55FB63FD91Q33347815-A06ED4BD-1815-45FB-92DE-E7BBC0450DEBQ33391761-79ACF26F-CB77-4560-BF3D-64FDEC98D7AFQ33648600-9BCAB4B1-4422-4918-9A63-ECDE6ACC92D6Q33857281-71EE5706-7BB3-452C-8127-F58B69C67E2BQ33896067-3AFD3884-7E49-49DB-9F0B-6D5A2AC5B69FQ33962894-D046DA93-EF1F-4193-89BD-B417B425E718Q33972274-98E09680-1F91-453C-9673-A28FB3D94C5CQ34116882-97BDED49-6E1B-494A-8353-0161293B9F0EQ34309475-C6C63949-08C2-452B-9ADD-44EF559EB752Q34316681-65C0F4E3-F4A7-4046-95A0-BE2137ABB5FCQ34352000-7E067443-5354-4AAA-A552-A41BEF4F683AQ34437450-F723B949-D4D3-461D-B19B-B6E2BE894DA9Q34481988-50347313-6193-4136-9B25-7171DCA29DF6Q34488183-77D06649-1181-432B-868A-759315E0971EQ34540706-ED67446D-5F0E-4285-9285-3E26EE1D8133Q34602894-5976A1A7-D0AF-4515-8175-9BA5A6F2DA01Q34614976-1A601B9E-DCF6-4160-9B7B-A91C8238059FQ34636796-4D9C7643-A2F4-4BF7-B0C6-8F5E91740CC8Q34658625-3AF0C1B5-7454-4CED-9327-1B6A06CB2AD5Q34658632-01BEB47B-1F5B-484E-BEE6-17DB1D6D1CD1Q34749550-31E124D1-72FF-4C4C-B809-7772BB67376CQ34769616-2EFB5079-0AC9-4D76-86C3-BFA914000935
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
V Soriano
@ast
V Soriano
@nl
V Soriano
@sl
Vicente Soriano
@en
Vicente Soriano
@es
type
label
V Soriano
@ast
V Soriano
@nl
V Soriano
@sl
Vicente Soriano
@en
Vicente Soriano
@es
altLabel
Vincent Soriano
@en
prefLabel
V Soriano
@ast
V Soriano
@nl
V Soriano
@sl
Vicente Soriano
@en
Vicente Soriano
@es
P214
P1053
O-5730-2018
P106
P1153
57208312072
7201761180
P214
P31
P496
0000-0002-4624-5199
P5008
P734
P7859
lccn-n2005185061